Gilead Sciences is trading at $129.30 (4.1% down) today following the announcement of a failed Phase 3 solid tumor clinical trial. - The decline also comes amidst increased Treasury yields, which are pressuring biotech sector valuations today. - Analysts may lower earnings forecasts due to delays in oncology portfolio sales timelines.